Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.22

+2.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (8225)	5/5/2003 9:11:52 AM
From: Icebrg	Read Replies (1) of 52153

Peter >>P.S. They say anything about the ED drug? Its class has been bedeviled by side effects (nausea).>> Nausea will perhaps not cause the same problems as those which have been seen for some of the drug's classmates. We will know in about a year's time according to NBIX. A quote from today's BioCentury. Erik The compound does have differences from other dopamine agonists in development, such as apomorphine. Henry Pan, executive vice president of clinical development and chief medical officer at NBIX, told BioCentury that PnU 142,774 is selective for dopamine D2 receptors. In contrast, apomorphine is a non-specific agonist of dopamine D1 and D2 receptors. We think that the specific agonist may reduce nausea and other side effects seen with apomorphineî such as hypotension, he said. These side effects are believed to be related to the D1 portion of apomorphineís mechanism.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next